Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Monsoon Presentation October 2020
12 slides from Actinogen Medical's conference presentation, Oct 28, 2020
Slide 1: Monsoon Presentation
MONSOON PRESENTATION Dr. Bill Ketelbey: CEO & MD October 2020 Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases
Slide 2: Xanamem – lead compound
Xanamem™ – lead compound Novel Mechanism of Action - designed to inhibit cortisol production in the brain (through inhibition of the 11β-HSD1 enzyme) Compelling results from various studies underpin further clinical development Pre-clinical long-term toxicology studies Phase II trial in Alzheimer’s
Slide 3: Key outcomes from Xanamem studies
Key outcomes from Xanamem studies Xanamem, an oral compound, demonstrated to be an efficacious, safe, brain penetrant, selective and effective 11β –HSD1 inhibitor producing significant pharmacodynamic effects on cortisol Cognitive Statistically significant clinical effect in improving cognition in h
Slide 4: Significant cognitive efficacy signal achieved
Significant cognitive efficacy signal achieved Breakthrough results demonstrate robust cognitive efficacy improvement in multiple cognition domains Working memory Visual attention Psychomotor function (One Back Test) (Identification Test) (Detection Test) Score Score Score P<0.01 P=0.05 P=0.09 Stron
Slide 5: Leveraging clinical development across multiple indications
Leveraging clinical development across multiple indications Alzheimer’s disease (AD) FXS selected as next Continued focus on Schizophrenia1 clinical development Alzheimer’s disease ? Fragile X opportunity syndrome (FXS) XanaMIA: Planned phase Potential clinical trials XanaFX: Planned phase II target
Slide 6: Mild Cognitive Impairment due to Alzheimer's disease
Mild Cognitive Impairment due to Alzheimer’s disease Planned phase II trial to link the compelling XanaHES results with an Alzheimer’s disease patient population Healthy elderly Mild Cognitive Mild Moderate Severe (20mg daily) Impairment due to AD (10mg daily) Pre-clinical & Prodromal Disease Alzhei
Slide 7: XanaMIA clinical trial
XanaMIA clinical trial Phase II trial to demonstrate the safety, tolerability and efficacy of Xanamem in patients with MCI due to AD Key design learnings incorporated into XanaMIA Key milestones ▪ Enriched eligibility criteria including biomarkers Commence recruitment in 1H CY211 ▪ 72 males & female
Slide 8: Anxiety, behavioural problems and sleep in Fragile X syndrome
Anxiety, behavioural problems and sleep in Fragile X syndrome FXS is a rare genetic condition representing a significant unmet medical need FXS is characterised by a range of developmental problems including: ▪ Learning disabilities ▪ Speech and language deficits ▪ Cognitive impairment ▪ Anxiety (~9
Slide 9: Clinical development underpinned by strategic benefits
Clinical development underpinned by strategic benefits Xanamem in FXS - attractive benefits provided by Orphan Drug and Rare Paediatric Disease Designations1,2 Regulatory Developmental Commercial Regulatory exclusivity / Increased speed to market and Direct commercial incentives, enhanced competitiv
Slide 10: XanaFX clinical trial
XanaFX clinical trial Phase II trial to demonstrate the safety and efficacy of Xanamem on anxiety, sleep, and behavioural problems in patients with Fragile X syndrome Proposed clinical trial design Key upcoming milestones ▪ Proof-of-concept study Planned to commence recruitment in 1H CY211 ▪ Double-
Slide 11: Attractive development pipeline
Attractive development pipeline Studies 2H CY20 1H CY21 2H CY21 Upcoming catalyst1 Trial to commence Mild cognitive impairment due to recruitment in 1H CY21 XanaMIA Trial planning Alzheimer’s disease Phase II trial Expected completion within 24 months Trial to commence Anxiety, sleep & behavioural p
Slide 12: Disclaimer
Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak
Actinogen Medical — Monsoon Presentation October 2020 on 6ix